studies, however, have involved small numbers of exposed cases (La Vecchia et al, 1982; Cramer et al, 1983; Kaufman et al, 1989) , have not distinguished unopposed oestrogen from oestrogen given in combination with progestogen (Booth et al, 1989; Hempling et al, 1997) , or have used hospital controls (Hartge et al, 1988; Booth et al, 1989; Kaufman et al, 1989; Hempling et al, 1997) with possible overestimation of general exposure rates (Rodriguez et al, 1995) . Hence, the issue is currently unresolved.
We report here the results of a large Australian case-control study in which the relation between HRT, and in particular unopposed ORT, and epithelial ovarian cancer, both overall and among histological types, was explored. We also examined any potential modification of the effect of ORT on ovarian cancer risk by tubal sterilization and hysterectomy.
METHODS
Histologically confirmed incident cases of primary epithelial ovarian cancer registered in major gynaecological-oncology treatment centres in three Australian states were ascertained. Cases diagnosed in 1991 and 1992 in New South Wales and Victoria, and from August 1990 to the end of 1993 in Queensland were recruited. The histological types of all cancers of women included in the study were reviewed by an independent gynaecological pathologist in each state, as described in detail elsewhere (Purdie Hormone replacement therapy and risk of epithelial ovarian cancer et al, 1995) . Briefly, ovarian cancer patients aged 18-79 years at diagnosis who were capable of completing the questionnaire were eligible to participate. A control series was selected at random from the electoral roll (enrolment to vote is compulsory in Australia) frequency matched to cases on age (20-year bands) and broad geographic region. Women with a history of ovarian cancer or bilateral oophorectomy, were not eligible to be controls; cases not on the electoral roll were excluded from the analysis.
Identically trained interviewers administered a standard questionnaire to each woman in a face-to-face interview to obtain personal details including education, height and weight, smoking history, family history of ovarian and other cancers, full reproductive and contraceptive histories and age at menopause. Questions were also asked about tubal sterilization and hysterectomy, and with the women's written consent, confirmation of these procedures was sought from relevant medical practitioners as described previously (Green et al, 1997a) .
Information was gathered about use of HRT, specifically the type of hormones, doses, age at first use and duration of use were recorded for up to three different types of treatment. Any HRT used by cases after diagnosis was not considered; and those using HRT at diagnosis were considered to be current users. HRT use in controls was treated similarly.
Relative risks of ovarian cancer, both overall and within subcategories, were estimated using multiple logistic regression to simultaneously adjust for age (in years), level of education, residential location, parity, duration of oral contraceptive pill use, talc use in the perineal region, body mass index (BMI), smoking status, hysterectomy and tubal sterilization (where appropriate) and a family history of breast or ovarian cancer (Purdie et al, 1995) . Women who had ever used unopposed ORT for at least 1 month were compared with those who had never used HRT, so women who had used other forms of HRT (63 cases and 74 controls) were excluded from the unopposed oestrogen analyses. Similar analyses were performed among women with and without a history of tubal sterilization or hysterectomy to assess potential effect modification from these procedures. Interactions between factors were assessed using the product term in the logistic regression models. All analyses were carried out using the SAS statistical package.
RESULTS
There were 793 eligible cases and 855 eligible controls in the study representing response rates of 90% and 73% respectively. Ovarian cancer was subdivided into five histological groups: serous (415, 52%); endometrioid and the related clear cell (164, 21%); mucinous (114, 14%); poorly differentiated adenocarcinomas (54, 7%); and mixed epithelial tumours with malignant mixed mesodermal/Müllerian tumours (44, 6%). Two cases with transitional cell (malignant Brenner) tumours were not included in the subtype analyses.
Overall, 131 cases (16.5%) and 149 controls (17.4%) reported ever taking any form of HRT for menopause-related reasons, which is consistent with cross-sectional data from a similar aged population-based Australian study (Dennerstein et al, 1994) . Of these, 68 cases (8.6%) and 75 controls (8.8%) reported ever using unopposed ORT. After adjustment for potential confounders, there were no significant associations found between occurrence of ovarian cancer and ever use of HRT, either overall or in its various forms (Table 1 ). There were also no clear trends in risk for increased duration of HRT use or time since last use, either overall or for the most common forms (Table 2) .
There was, however, higher use of ORT among cases with endometrioid or clear cell cancers than among controls or other cases and, after adjustment for potential confounders, a marked and significant elevation in risk among this group of cases was observed (Table 3) . A comparison of the effect in endometrioid or clear cell tumours with the effect in other tumour types approached significance (P = 0.06). The separate risks for endometrioid and for clear cell tumours were nearly identical.
Women who reported having either a hysterectomy or tubal sterilization had higher usage of HRT, in particular unopposed oestrogen: 30% of women with a hysterectomy and 15% of women with a tubal sterilization had ever used ORT, compared with only 6% of women without such surgery. These women were also at lower risk of ovarian cancer (Green et al, 1997b) . We therefore examined whether hysterectomy or tubal sterilization, as well as being confounders, modified the relationship between ever use of ORT and ovarian cancer risk. For all cases, an inverse association between unopposed oestrogen use and ovarian cancer was seen in women with a prior hysterectomy, and no relationship was seen in those with tubal sterilization alone. In contrast, women who reported neither hysterectomy nor tubal sterilization exhibited a moderately strong and significant increase in risk associated with ORT (Table 4 ). The interaction effects between hysterectomy and ORT and between tubal sterilization and ORT among those women without a hysterectomy were significant (P = 0.006 and 0.04 respectively). Relative risks of unopposed oestrogen therapy were also higher for endometrioid and clear cell tumours than for other tumours among women with a prior hysterectomy or tubal sterilization and strikingly so among those without surgery (Table 4) . The effect of ORT was essentially uniform across the different levels of duration of use, irrespective of surgical history or histological type of tumour. There was, however, a distinct decrease in risk of ovarian cancer seen with increasing time since last use among women with an intact reproductive system. In this group, compared with never-users of HRT, current ORT users were at highest risk (OR 3.92; 95% CI 1.32-11.6); women who had ceased use within the last 5 years were at intermediate risk (OR 2.09; 95% CI 0.90-4.89); and women who had last used oestrogen more than 5 years ago were at lowest risk (OR 1.45; 95% CI 0.90-2.32). No similar trend in risk with time since last use of ORT was apparent in those with a previous hysterectomy or tubal sterilization.
Oestrogen doses were too poorly reported by subjects for a useful analysis.
No associations similar to those seen with unopposed oestrogen were found for any other form of HRT.
DISCUSSION
A non-significant 20% increase in risk of ovarian cancer was found to be associated with ever use of HRT, which is consistent with summary estimates reported in a recently published meta-analysis on the subject (Garg et al, 1998) . Ovarian carcinomas are, however, a heterogeneous collection, morphologically, pathogenically and aetiologically (Russell, 1994) . Many epidemiological studies have assumed homogeneity for the purposes of studying general aetiological factors. An important outcome has been revealed in the histological subtype analysis of this case-control study, namely, the moderately strong association found between ever use of unopposed oestrogen and endometrioid or, the closely related, clear cell tumours. This parallels the findings of a number of certain other studies that looked specifically at endometrioid ovarian cancers (La Vecchia et al, 1982; Weiss et al, 1982; Cramer et al, 1983; Risch, 1996) , although not all (Hartge et al, 1988; Booth et al, 1989; Kaufman et al, 1989; Whittemore et al, 1992; Hempling et al, 1997) . Endometrioid and clear cell tumours are broadly regarded as the equivalent of the same cancers in the endometrium (showing proliferative, or 'pregnancy-related' secretory changes), whereas serous tumours are neoplastic analogues of the fallopian tube mucosa and mucinous tumours are similar to those of the endocervix or colon (Scully, 1977 ). An analogy can therefore be drawn between our findings and those in endometrial cancer in which the relationship with oestrogens is most marked for the endometrioid and least strong for serous papillary carcinomas (Bokham, 1983; Smith and McCartney, 1985) .
It is clear that the aetiology of endometrial adenocarcinomas is linked to the role of oestrogens (IARC, 1987) . That endometrial adenocarcinoma is a 'generic diagnosis' and represents a heterogeneous group of neoplasms is also clear, as it is for ovarian cancers (Greven and Corn, 1997) .
A finding of interest was that unopposed ORT was inversely associated with all ovarian cancers in women with a prior hysterectomy (although not significantly), but positively associated in women without either hysterectomy or tubal sterilization. In women with tubal sterilization no association was observed. While this is not the first study to report a lower risk of ovarian cancer associated with ORT among women with a hysterectomy (Whittemore et al, 1992; Hartge et al, 1988) , others have reported a larger effect of ORT in this group (Booth et al, 1989; Kaufman et al, 1989) or no difference (Risch, 1996) . However, no previous study has examined the effect of ORT stratified by hysterectomy and tubal sterilization. The association seen here may imply that non-contraceptive-oestrogen is a risk factor specifically for women with an intact genital tract. In all categories of surgical history, the endometrioid/clear cell group of tumours retained their elevated risk relative to other tumour types. In addition, among women with an intact genital tract, there was also a noticeable decrease in risk with increasing time since last use of unopposed oestrogen, consistent with the type of association with endometrial carcinomas found by some (Green et al, 1996) , though not all studies (Paganini-Hill et al, 1989) .
The positive links seen with ORT may reflect the suggested role of ovarian endometriosis in the aetiology of endometrioid or clear cell ovarian cancer (Sainz de la Cuesta et al, 1996) . Postmenopausal ORT could cause proliferation of the uterine endometrium, and in women with an intact genital tract, could therefore increase the risk of retrograde menstruation (Metzger and Haney, 1989) . This, in combination with the increased levels of circulating oestrogens from the oestrogen therapy, could promote ovarian endometriosis (Faulkner and Riemenschneider, 1945) . Women without hysterectomy or tubal sterilization who are prescribed unopposed oestrogen may therefore have an increased risk of subsequent ovarian endometriosis and consequently have a higher risk of endometrioid or clear cell ovarian cancer (Sainz de la Cuesta et al, 1996; Paulson, 1997) .
Contrary to what might be expected given the well-established association between oestrogen and endometrial adenocarcinoma, unopposed oestrogen was prescribed for some women with an intact uterus in our study until quite recently. Year of first use is, therefore, unlikely to be a major confounding factor. Further, among the 73 women who both used unopposed oestrogen and had a hysterectomy, only three began use of oestrogen before the operation and all three continued use after surgery.
We do not believe that selection or recall biases could have accounted for our finding (Purdie et al, 1995) . It is unlikely the results could be explained by incorrect reporting of operations since self-reported histories of hysterectomy and tubal sterilization were checked against available medical reports and 96% and 88% respectively were confirmed (Green et al, 1997a HRT, which did not show similar effects. However, many of the associations observed in this investigation of HRT were based on small numbers: only 18 cases of endometrioid or clear cell ovarian cancer had ever used unopposed ORT. When further subdivided by history of gynaecological surgery, this problem was even more pronounced.
Prior efforts to evaluate the effects of menopausal oestrogenic agents on ovarian carcinomas as a whole have been inconsistent, some studies showing an increase in risk (Weiss et al, 1982 ) some a decrease (Hartge et al, 1988; Hempling et al, 1997) and others no significant effect (La Vecchia et al, 1982; Kaufman et al, 1989; Purdie et al, 1995) . These inconsistencies may be due to the histological type-specific associations observed in these data, as well as to the effect modification observed with certain genital tract surgery. Those studies that examined the effect of menopausal oestrogen separately for the different types of ovarian cancer have also yielded contradictory findings. Those not finding a positive association more often used hospital based controls (Hartge et al, 1988; Booth et al, 1989; Kaufman et al, 1989; Hempling et al, 1997) , which may reflect an excess of HRT use among hospitalized women (Rodriguez et al, 1995) .
In conclusion, our results are consistent with the possibility that some utero-ovarian carcinogenic influence, such as endometriosis, is promoted by ORT, increasing the risk of endometrioid and clear cell ovarian carcinomas.
